In short

  • The source says Wegovy 7.2 mg was not available on the NHS when the article was written.
  • It says the dose had MHRA approval but still needed a NICE assessment before NHS availability.
  • The source says patients should have used 2.4 mg for at least four weeks before moving to 7.2 mg.

The new 7.2 mg dose of Wegovy has just been approved in the UK. If you’re already on Wegovy as a weight loss treatment (maybe you’re on the maximum 2.4 mg Wegovy dosage) you might be wondering when this higher dose will be available through the NHS.

The short answer is: not immediately. Here’s what you need to know about NHS availability and what happens next.

Is Wegovy 7.2 mg Available on the NHS?

No, the highest strength of Wegovy isn’t currently available on the NHS.

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the 7.2 mg dose on 6 January 2026. This means it’s licensed for use in the UK. However, it doesn’t automatically mean the NHS will fund it.

Right now, you can only access Wegovy 7.2 mg through private providers like us.

For NHS availability, the medication needs to go through an additional assessment by the National Institute for Health and Care Excellence (NICE). Unfortunately, this process is just beginning.

How NHS Approval Works

Getting a new dose approved for NHS use involves two separate steps.

The MHRA reviews clinical trial data to make sure the medication is safe and effective. This is complete for Wegovy 7.2 mg.

NICE then reviews whether the treatment represents good value for money for the NHS. They look at clinical effectiveness, cost per patient, quality of life impact, and budget implications.

Only after NICE approves a medication does the NHS have a legal obligation to fund it.

How Long Could Approval Take?

Based on previous examples, NICE assessment typically takes six to nine months after MHRA approval.

To put this into perspective, the standard 2.4 mg Wegovy dose had MHRA approval in September 2021. NICE approved it in March 2023, and it then became available on the NHS in September 2023.

For the 7.2 mg dose, the timeline should be quicker since it’s a new dose of an existing treatment, rather than a completely new drug.

A realistic estimate for NHS availability is late 2026 to early 2027, assuming NICE completes its assessment within six to nine months and recommends the treatment.

What to Do In the Meantime

If you want to switch to Wegovy 7.2 mg, you have options while waiting for the NICE evaluation to finish.

Continue on Your Current Dose

If you’re doing well on Wegovy 2.4 mg, there’s no need to increase your dose. The 7.2 mg dose is designed for people who’ve plateaued on 2.4 mg or need additional support. It’s suitable for patients who aren’t experiencing bad side effects of Wegovy.

Consider Private Prescription

You can access Wegovy 7.2 mg now with a private prescription. At Simple Online Pharmacy, the 7.2 mg dose costs £329 per month.

Before you are eligible for the higher dose, you’ll need to have been on the 2.4 mg dose for at least four weeks.

Speak to Your Specialist Team

If you’re under an NHS specialist for weight management, talk to your team about your progress. They can advise whether the higher dose might be suitable and keep you updated on NHS availability.

If you can afford it, a private prescription gives you quicker access. Otherwise, continue with your current treatment and stay in touch with a healthcare professional.

Key Takeaways

  • The 7.2 mg dose of the Wegovy weight loss injection is not currently available on the NHS.
  • MHRA approved the dose in January 2026, but NICE assessment is still needed.
  • NHS availability is estimated for late 2026 to early 2027.
  • Private prescription is available now at £329 per month through Simple Online Pharmacy.
  • You must be on 2.4 mg for at least four weeks before switching to 7.2 mg.
  • If you’re doing well on 2.4 mg, there’s no need to switch.

Sources

References

This page lists 3 sources. Each citation is presented as it appeared in the cited publication.

  1. Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only, MHRA [Accessed: 10 February 2026]

  2. 1966-LB: Efficacy and safety of semaglutide 7.2 mg in obesity—STEP UP Trial. Diabetes, 74(Supplement_1) [Accessed: 10 February 2026]

  3. Introducing new medicines in the NHS in the UK – pathway, UK Government [Accessed: 10 February 2026]

Reference links open the cited source pages. If you spot something out of date, tell our content team.

Who wrote this

Written and reviewed by our team

Authored by

Kate Breen

Content Writer

Kate Breen is a content writer at Simple Online Pharmacy. With 4.5 years of experience across various industries, she specialises in healthcare writing. She holds a BSc in Biology and has worked with healthtech companies, pharmaceutical brands and private clinics. As a chronic illness patient herself, Kate is passionate about making healthcare information accessible by removing jargon and easing patient concerns.

Read Kate’s profile

Medically reviewed by

Richard Wood, Pharmacist

Richard Wood

Pharmacist / Clinical Specialist

GPhC 2078802 · verify

Richard is a pharmacist and content reviewer at Simple Online Pharmacy. He officially joined the team in 2024 after several years of working with the company as a contractor. Prior to that, he spent over 11 years as a community pharmacist, building a strong foundation in patient care.

Read Richard’s profile

Published

Last medically reviewed

Sources cited

See 3 references

We'd love your feedback - Was this article helpful?

Keep reading

More Wegovy advice

View all Wegovy advice